Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Inclusion Criteria

• •Patients diagnosed with histologically confirmed ovarian stromal tumor (granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor \[androblastoma\], steroid \[lipid\] cell tumor, gynandroblastoma, unclassified sex cord stromal tumor, sex cord tumor with annular tubules)
• •Patients must have recurrent stromal tumor having received no more than one prior chemotherapy regimen
• •Patients must have measurable disease as defined by Gynecological Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• •White blood count equal to or greater than 3000/mcl
• •Granulocyte count equal to or greater than 1500/mcl
• •Platelet count equal to or greater than 100,000/mcl
• •Creatinine equal to or less than 2.0 mg%
• •Bilirubin less than or equal to 1.5 times normal
• •Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3 times normal
• •Patients with a GOG performance grade of 0, 1 or 2
• •Patients of child bearing potential must have a negative pregnancy test and must agree to practice an effective means of birth control
• •Patients who have met the pre-entry requirements as specified
• •Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization